Translate
Zentalis Pharmaceuticals Llc
About
Zentalis Pharmaceuticals Llc (NASDAQ:ZNTL) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 21 2026
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer
Apr 17 2026
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026
Apr 9 2026
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Mar 26 2026
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates
Mar 17 2026
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
Recent Videos
ZNTL Stock Analysis | Zentalis Pharmaceuticals, Inc. | April 15, 2026
Apr 15, 2026
ZNTL Stock Analysis | Zentalis Pharmaceuticals, Inc. | April 14, 2026
Apr 14, 2026
Zentalis Pharmaceuticals just filed an 8-K with the SEC. Material event. April 9, ... #Shorts
Apr 13, 2026
Biotech Semanal: Cue, Zentalis y Estrella (+100%) y el drama de Replimune.
Apr 13, 2026
Financials
Revenue
$26.86 M
Market Cap
$190.8 M
EPS
-1.91